Meningococcal group B vaccine (Novartis)

Bๅž‹่„‘่†œ็‚Ž็ƒ่Œ็–ซ่‹—๏ผˆ่ฏบๅŽ๏ผ‰

Report date: 2025/12/19 15:44:53

Base Information

Drug NameMeningococcal group B vaccine (Novartis)
Drug Alias NameB็พค่„‘่†œ็‚Ž็ƒ่Œ็–ซ่‹—๏ผˆ่ฏบๅŽ๏ผ‰Bexsero4CMenBGSK-3536829
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Biological material > Bacterial vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsUterine Cervical DiseasesMeningitisAnus Diseases +[7]ย 
Global Approved IndicationsMeningitis, Meningococcal
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2013/01/13
Country/TerritoryCzechiaUnited StatesThailand +[12]ย 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesChinese University Of Hong Kong (Cuhk)Glaxosmithkline PlcKirby Institute +[6]ย 
Inactive CompaniesNovartis Vaccines
Active IndicationsUterine Cervical DiseasesMeningitisAnus Diseases +[6]ย 
Inactive IndicationsMeningococcal Infections

Other Information

ATC CodeJ07AH09
Related LinksN/A